Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Financing › Details

Epigenomics–SEVERAL: investment, 201704–201707 public cash takeover offer €7.52/share FAILED valuing ECX at €171m incl net cash by CFUC + Biochain

 

Period Period 2017-04-26 ďż˝ 2017-07-12
  Predecessor Epigenomics–BioChain: investment, 201410 acquisition €4.2m 1.35m new shares €3.08/share by BioChain Institute Inc
Organisation Money taker Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY)
  Group Epigenomics (Group)
Products Product Epi proColon® blood test
  Product 2 finance
  Index term 2 Epigenomics–BioChain: investment, 201410 acquisition €4.2m 1.35m new shares €3.08/share by BioChain Institute Inc
     

Epigenomics AG. (7/12/17). "Press Release: Epigenomics AG – Voluntary Public Takeover Offer by Summit Hero Holding Not Successful". Berlin.

Summit Hero Holding GmbH (“bidder”) announced today that, as of expiry of the extended acceptance period at midnight (24:00 CEST) on July 7, 2017, 62.13 percent of Epigenomics outstanding shares have been tendered under the voluntary public takeover offer or were held by or attributed to the bidder. Consequently, the minimum acceptance threshold of 75.0 percent has not been reached.

Greg Hamilton, CEO of Epigenomics, commented: „It is unfortunate that the takeover offer has not been successful. We now will carefully explore alternative financing options for Epigenomics in order to successfully commercialize our products and develop innovative cancer tests.”


Contact:

Epigenomics AG, Investor Relations, Peter Vogt, Geneststrasse 5, 10829 Berlin, Tel +49 (0) 30 24345 386, Fax +49 (0) 30 24345 555, E-Mail: ir@epigenomics.com


About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon®, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epigenomics’ second product, Epi proLung®, is in development as a blood-based test for lung cancer detection.

For more information, please visit www.epigenomics.com.

   
Record changed: 2019-06-09

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Epigenomics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top